Grant Title: BEHAVIORAL AND INTEGRATIVE TREATMENT DEVELOPMENT PROGRAM (R01, R03, R34)

Funding Opportunity Number: PA-10-012. CFDA Number(s): 93.272, 93.279, 93.361.

Agency/Department: Department of Health and Human Services, National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), National Institute on Alcoholism and Alcohol Abuse (NIAAA), and National Institute of Nursing Research (NINR).

Area of Research: Research to improve treatment for drug and alcohol abuse and dependence.


Application Deadline: R01-New: February 5, June 5, October 5 annually; Resubmissions: March 5, July 5, November 5 annually; R03, R34-New: February 16, June 16, October 16 annually; Resubmissions: March 16, July 16, November 16 annually.

Amount: R01: Not limited in dollars but need to reflect the actual needs of the proposed project; R03: Direct costs of up to $50,000 per year; R34: Direct costs are limited to $450,000, with no more than $225,000 per year.

Length of Support: R01: Up to 5 years; R03: Up to 2 years. R34: Up to 3 years.

Eligible Applicants: Public and State controlled institutions of higher education. See the full announcement for a complete list of eligible applicants.

Summary: The purpose of the R01 is to encourage Stage II or Stage III research to conduct clinical trials, examine mechanisms of behavior change, determine dose-response, optimize combinations, and/or ascertain best sequencing of behavioral, combined, sequential, or integrated behavioral and pharmacological. The purpose the R03 is to encourage early career investigators or investigators who are striving to make a shift in their research to propose discrete, well-defined projects that can be completed within two years with limited resources. Specific examples include: 1) Stage I pilot or feasibility studies; 2) secondary analysis of existing data; 3) small, self-contained research projects; 4) development of research assessments or methodology; and 5) development of new research technology. The purpose of the R34 is to advance evidence-based treatment research through 1) the development, manualization, standardization, early-stage efficacy and/or pilot testing of novel or adapted treatments and/or interventions (i.e. Stage 1 treatment research, see below), 2) the refinement, modification, adaptation and/or pilot testing of interventions with demonstrated efficacy for use in broader scale efficacy or effectiveness trials, or 3) novel treatment research that requires preliminary testing or development. It is expected that R34 research conducted will primarily consist of Stage I treatment development research that will provide feasibility, tolerability, and acceptability information and/or pilot data for larger scale Stage II or Stage III behavioral and integrative treatment studies. The R01, R03 and R34 FOA seeks to support research, as described above, within the domains of behavioral, combined, sequential, or integrated behavioral and pharmacological (1) drug abuse treatment interventions, including interventions for patients with comorbidities, in diverse settings; (2) interventions to prevent the acquisition or transmission of HIV infection among individuals in drug abuse treatment; (3) interventions to promote adherence to drug abuse treatment, HIV and addiction medications; and (4) interventions to treat chronic pain.